Clinical Trial

iTBS for Increased Appetite Induced by Antipsychotics

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2025 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-03-13; most recent amendment 2025-03-22.
Status change: Not Yet Recruiting → Recruiting 2023-12-06
Trial Details
NCT Number NCT05783063
Lead Sponsor Central South University
Conditions Schizophrenia
Enrollment 60 participants
Start Date 2023-08-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-26